Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED

CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who rece...

Descripción completa

Detalles Bibliográficos
Autor principal: Aragon-Ching, Jeanny B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Invited Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854101/
https://www.ncbi.nlm.nih.gov/pubmed/26510505
http://dx.doi.org/10.4103/1008-682X.164920
_version_ 1782430182968131584
author Aragon-Ching, Jeanny B
author_facet Aragon-Ching, Jeanny B
author_sort Aragon-Ching, Jeanny B
collection PubMed
description CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer. In addition to overall survival, secondary endpoints such as time to castration resistance, PSA response were also significant for the patients who received early chemotherapy.
format Online
Article
Text
id pubmed-4854101
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-48541012016-05-10 Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED Aragon-Ching, Jeanny B Asian J Androl Invited Research Highlight CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer. In addition to overall survival, secondary endpoints such as time to castration resistance, PSA response were also significant for the patients who received early chemotherapy. Medknow Publications & Media Pvt Ltd 2016 2015-10-27 /pmc/articles/PMC4854101/ /pubmed/26510505 http://dx.doi.org/10.4103/1008-682X.164920 Text en Copyright: © Asian Journal of Andrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Invited Research Highlight
Aragon-Ching, Jeanny B
Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
title Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
title_full Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
title_fullStr Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
title_full_unstemmed Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
title_short Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
title_sort use of early chemotherapy for hormone-sensitive prostate cancer: time for chaarted
topic Invited Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854101/
https://www.ncbi.nlm.nih.gov/pubmed/26510505
http://dx.doi.org/10.4103/1008-682X.164920
work_keys_str_mv AT aragonchingjeannyb useofearlychemotherapyforhormonesensitiveprostatecancertimeforchaarted

Ejemplares similares